HOME >> MEDICINE >> NEWS
Synbiotic modulation of gut flora improves minimal hepatic encephalopathy in cirrhotic patients

Some cirrhotic patients develop brain dysfunction, called hepatic encephalopathy, which causes deficits in behavior, intelligence, consciousness and neuromuscular function. When the dysfunction is minor, it is called minimal hepatic encephalopathy (MHE). Since ammonia has been shown to play a key role in overt hepatic encephalopathy, treatment options for MHE have also focused on reducing ammonia levels in the body.

A new study published in the May 2004 issue of Hepatology has shown that treating cirrhotic patients with synbiotics or fermentable fiber can alter the flora in the gut, lowering its pH levels as well as the ammonia levels in the blood. Both treatments improved clinical signs of brain and liver dysfunction. They may be useful alternatives to lactulose for the management of MHE.

Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD), published by John Wiley & Sons, Inc., is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

To consider the effect of synbiotics and fermentable fiber on gut flora and MHE, a collaborative research team from Beijing Youan Hospital and Capital University of Medical Sciences, China, University College London, England and the Prince of Wales Hospital, Sydney, Australia conducted a pilot, placebo-controlled study of 55 individuals with MHE. Twenty of the patients were treated for 30 days with a daily symbiotic preparation. Twenty took fermentable fibers for 30 days, and fifteen received a placebo treatment for 30 days. At 30 days, all patients were re-screened for MHE. The researchers also assessed gut flora in fecal samples at day 1, day 30, and day 44. They compared their findings with the gut flora of 20 normal healthy volunteers.

After 30 days of treatment, 50 percent of patients treated with either the synbiotic preparation or ferment
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
13-May-2004


Page: 1 2 3

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
3. New substance that improves the photodetection of bladder cancer gains market approval
4. Most advanced CT scanner improves imaging of heart, avoids need for surgical inspection
5. Columbia study finds hemophilia therapy dramatically improves outcomes for bleeding stroke
6. New test improves detection of bladder cancer
7. Adding radiation therapy to chemotherapy improves survival in patients with high-risk breast cancer
8. Care of rural stroke patients improves with telephone support
9. Acupuncture relieves pain and improves function in knee osteoarthritis
10. Daily social/physical activity improves sleep and cognition in the elderly
11. Stanford study finds new method improves chemotherapy survival in mice

Post Your Comments:
(Date:7/25/2014)... (PRWEB) July 25, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Ibuprofen and Oxcarbazepine ... that one lot of Ibuprofen and one lot of Oxcarbazepine ... due to mislabeled packaging. Oxcarbazepine is used for the treatment ... , The reason for the recall is that Lot ...
(Date:7/25/2014)... July 25, 2014 Parker Waichman LLP, ... of consumers comments on a recent tobacco lawsuit in ... smoker $23.6 billion in punitive damages. Cynthia Robinson brought ... cigarettes. The case is Cynthia Robinson v. R.J. Reynolds ... Florida First Circuit Court, Escambia County, Florida; Case Number ...
(Date:7/25/2014)... Drexel University College of Medicine is pleased ... been appointed vice dean for education, effective October 1, 2014. ... Medical College, where she is currently chair of the Department ... of medicine. , As a member of the senior ... major role in many aspects of the development of the ...
(Date:7/25/2014)... vulnerable neurons and reduce motor deficits in a ... University School of Medicine have shown. , The ... Parkinson,s Disease . , The findings demonstrate that ... at sufficient levels and have beneficial effects when ... Previous studies of XPro1595 in animals tested more ...
(Date:7/25/2014)... 25, 2014 The new report ... Feed, Pharmaceuticals and Others), by Type (Amylases, Cellulases, ... Geography - Global Trends & Forecasts to 2019", ... of the global Carbohydrase market with analysis of ... is segmented and values are forecasted on the ...
Breaking Medicine News(10 mins):Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
(Date:7/24/2014)... July 24, 2014 Amgen (NASDAQ: AMGN ... financial results on Tuesday, July 29, 2014, after the close ... by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, ... Live audio of the conference call will be simultaneously broadcast ...
(Date:7/24/2014)... British Columbia and MENLO PARK, Calif. ... Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today that ... company,s fiscal year from December 31 to June 30. Accordingly, ... September 30, 2014. Jeffrey Bacha , president ... end is an important step in achieving our goal of ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
Cached News: